

Richard N Formica

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/694794/publications.pdf>

Version: 2024-02-01

48
papers

1,488
citations

430874

18
h-index

330143

37
g-index

49
all docs

49
docs citations

49
times ranked

1993
citing authors

#	ARTICLE	IF	CITATIONS
1	New National Allocation Policy for Deceased Donor Kidneys in the United States and Possible Effect on Patient Outcomes. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 1842-1848.	6.1	338
2	Adverse Outcomes of Tacrolimus Withdrawal in Immune-Quiescent Kidney Transplant Recipients. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 3114-3122.	6.1	172
3	The Kidney Allocation System. <i>Surgical Clinics of North America</i> , 2013, 93, 1395-1406.	1.5	131
4	Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin. <i>Neuropsychopharmacology</i> , 2020, 45, 990-997.	5.4	127
5	Changes in Use of Left Ventricular Assist Devices as Bridge to Transplantation With New Heart Allocation Policy. <i>JACC: Heart Failure</i> , 2021, 9, 420-429.	4.1	64
6	Report of National Kidney Foundation Consensus Conference to Decrease Kidney Discards. <i>Clinical Transplantation</i> , 2019, 33, e13419.	1.6	61
7	A randomized trial comparing losartan with amlodipine as initial therapy for hypertension in the early post-transplant period. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 1389-1394.	0.7	53
8	Consensus conference on heart-kidney transplantation. <i>American Journal of Transplantation</i> , 2021, 21, 2459-2467.	4.7	49
9	Analysis of Biomarkers Within the Initial 2 Years Posttransplant and 5-Year Kidney Transplant Outcomes. <i>Transplantation</i> , 2018, 102, 673-680.	1.0	44
10	Safety, pharmacokinetics, and pharmacodynamic activity of obinutuzumab, a type 2 anti-CD20 monoclonal antibody for the desensitization of candidates for renal transplant. <i>American Journal of Transplantation</i> , 2019, 19, 3035-3045.	4.7	44
11	Discovery and Validation of a Urinary Exosome mRNA Signature for the Diagnosis of Human Kidney Transplant Rejection. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 994-1004.	6.1	44
12	Simultaneous Liver-Kidney Transplantation: Impact on Liver Transplant Patients and the Kidney Transplant Waiting List. <i>Current Transplantation Reports</i> , 2018, 5, 1-6.	2.0	38
13	Developing simultaneous liver-kidney transplant medical eligibility criteria while providing a safety net: A 2-year review of the OPTN's allocation policy. <i>American Journal of Transplantation</i> , 2021, 21, 3593-3607.	4.7	30
14	A One-Day Centralized Work-up for Kidney Transplant Recipient Candidates: A Quality Improvement Report. <i>American Journal of Kidney Diseases</i> , 2012, 60, 288-294.	1.9	24
15	Simultaneous liver kidney transplantation. <i>Current Opinion in Nephrology and Hypertension</i> , 2016, 25, 577-582.	2.0	23
16	A critical assessment on kidney allocation systems. <i>Transplantation Reviews</i> , 2017, 31, 61-67.	2.9	23
17	Outpatient Management of the Kidney Transplant Recipient during the SARS-CoV-2 Virus Pandemic. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 892-895.	4.5	23
18	Integrase strand transferase inhibitors: the preferred antiretroviral regimen in HIV-positive renal transplantation. <i>International Journal of STD and AIDS</i> , 2017, 28, 447-458.	1.1	21

#	ARTICLE	IF	CITATIONS
19	Cytomegalovirus Glomerulopathy and Cytomegalovirus Interstitial Nephritis on Sequential Transplant Kidney Biopsies. <i>American Journal of Kidney Diseases</i> , 2014, 63, 536-539.	1.9	18
20	Opting out: confidentiality and availability of an "alibi"™ for potential living kidney donors in the USA: Table A1. <i>Journal of Medical Ethics</i> , 2015, 41, 506-510.	1.8	17
21	Economic Evaluation of Extending Medicare Immunosuppressive Drug Coverage for Kidney Transplant Recipients in the Current Era. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 218-228.	6.1	13
22	Passage of the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act: a Chance to Celebrate and Reflect. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 774-776.	6.1	13
23	The Broader Sharing of Deceased Donor Kidneys Is an Ethical and Legal Imperative. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 1174-1176.	6.1	12
24	Changing the Kidney Allocation System: a 20-Year History. <i>Current Transplantation Reports</i> , 2016, 3, 39-44.	2.0	11
25	Impact of the new heart allocation policy on patients with restrictive, hypertrophic, or congenital cardiomyopathies. <i>PLoS ONE</i> , 2021, 16, e0247789.	2.5	11
26	Kidney Transplantation and HIV. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 924-928.	4.5	10
27	Perspectives on the Strengths and Weaknesses of the National Kidney Allocation System. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 2056-2056.	4.5	9
28	Transition probabilities between changing sensitization levels, waitlist activity status and competing-risk kidney transplant outcomes using multi-state modeling. <i>PLoS ONE</i> , 2017, 12, e0190277.	2.5	9
29	A call to action: Feasible strategies to reduce the discard of transplantable kidneys in the United States. <i>Clinical Transplantation</i> , 2020, 34, e13990.	1.6	8
30	Mechanical ventilation at the time of heart transplantation and associations with clinical outcomes. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 843-851.	1.0	8
31	Patient and Clinician Perceptions of Informed Consent and Decision Making About Accepting KDPI > 85 Kidneys. <i>Transplantation Direct</i> , 2022, 8, e1254.	1.6	7
32	Advancing American Kidney Health: New Opportunities for Collaborative Care. <i>American Journal of Medicine</i> , 2020, 133, e335-e337.	1.5	6
33	Cytomegalovirus-related Complications and Management in Facial Vascularized Composite Allotransplantation: An International Multicenter Retrospective Cohort Study. <i>Transplantation</i> , 2022, 106, 2031-2043.	1.0	5
34	And equal access for all? The future of deceased donor kidney allocation. <i>American Journal of Transplantation</i> , 2018, 18, 1837-1838.	4.7	3
35	Improving Transplant Program Performance Monitoring. <i>Current Transplantation Reports</i> , 2021, 8, 293-300.	2.0	3
36	The Role of Procurement Biopsies in Kidney Acceptance Decision Making and Kidney Discard: Perceptions of Physicians, Nurse Coordinators, and OPO Staff and Directors. <i>Transplantation Direct</i> , 2022, 8, e1299.	1.6	3

#	ARTICLE	IF	CITATIONS
37	A Composite End Point of Graft Status and eGFR at 1 Year to Improve the Scientific Registry of Transplant Recipients'™ Five-Tier Rating System. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 1613-1624.	6.1	3
38	Allocating Deceased Donor Kidneys to Sensitized Candidates. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 377-378.	4.5	2
39	Opportunities to Increase Availability of Deceased Donor Kidneys. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 871-873.	4.5	2
40	Being Thoughtful about Desensitization. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 1878-1880.	4.5	2
41	Uncertainty in organ allocation is a catalyst for positive change. <i>American Journal of Transplantation</i> , 2021, 21, 1996-1997.	4.7	2
42	Transplantation of Kidneys from HCV Viremic Donors in the United States: A Missed Opportunity to Inform Clinical Decision Making and Health Policy. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 1778-1780.	6.1	1
43	Sustained Improvement in Patient Experience by Optimizing Patient Flow in Ambulatory Settings. <i>Journal of Patient Experience</i> , 2022, 9, 237437352210926.	0.9	1
44	When and how should immunosuppression be tapered for the failed renal allograft?. <i>Seminars in Dialysis</i> , 2011, 24, 371-373.	1.3	0
45	The role of the kidney in combined liver&€kidney transplantation. <i>Liver Transplantation</i> , 2018, 24, 164-165.	2.4	0
46	ESKD Risk in Living Kidney Donors &€œLike Me&€•. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 970-971.	4.5	0
47	Should the United States employ free market practices to solve the hidden public health crisis of chronic kidney disease?. <i>American Journal of Transplantation</i> , 2020, 20, 1217-1218.	4.7	0
48	It Is Time for Patient-Reported Outcome Measures to Be Included in the Approval Process for Solid Organ Transplant Medications. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 2984-2986.	6.1	0